Catalyst Wire Dossier Catalyst Wire Dossier

Mirvetuximab soravtansine

mirvetuximab soravtansine · ImmunoGen, Inc.
Drug timelines are a Plus or Pro feature.

16 regulatory and trial events tracked for Mirvetuximab soravtansine, covering 2018-07-05 to 2026-06-02. Get the full timeline:

Most recent: Clinical Trial Update: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer [Phase 3]

See pricing